Maha FDA Sampling Finds 5% Meds Substandard

Mumbai:  Nearly 5% of medicines sold at city’s pharmacies have been found to be of sub-standard by the Food And Drug Administration (FDA). A case has also been registered against drug manufacturers for selling substandard medicines, which can adversely affect citizens’ health.

As per FDA data, 2,530 medicines samples were collected from April to October across Mumbai, of which 124 were found to be sub-standard. “Every month, samples of seven medicines are taken from drug stores and sent to laboratory testing. Of these, about 2,000 samples of allopathy, 415 of ayurveda and homeopathy medicines were taken,” said an FDA official.

During the financial year 2019-20 (660 out of 8378 samples), 2020-21 (464 out of 7632), 2021-22 (364 out of 5146) and 2022-23 (468 out of 12790) found sub-standard.

FDA Drug Joint Commissioner Bhushan Patil said they continuously collect and test random samples at their labs in Mumbai, Nagpur and Sambhajinagar. “A case is registered in the court against pharmaceutical companies that fail to meet the quality standards, following which their manufacturing license is suspended or cancelled,” he said.

  • Related Posts

    Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

    New Delhi: In a major crackdown on the sale of expired and substandard products, the Central Range team of Delhi Police Crime Branch has arrested one person and seized nearly…

    FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

    Washington:  On March 18, 2026, the U.S. Food and Drug Administration (FDA) issued a draft guidance titled General Considerations for the Use of New Approach Methodologies in Drug Development. The…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

    Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

    FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

    FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

    IPC releases draft NFI-2026 to promote rational use of medicines

    IPC releases draft NFI-2026 to promote rational use of medicines

    Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

    Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

    US market to dent India pharma earnings even as domestic growth remains firm

    US market to dent India pharma earnings even as domestic growth remains firm

    Biocon Pharma receives USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg

    Biocon Pharma receives USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg